PL391988A1 - Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania odpowiedzi immunologicznej na tle zapalnym - Google Patents
Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania odpowiedzi immunologicznej na tle zapalnymInfo
- Publication number
- PL391988A1 PL391988A1 PL39198802A PL39198802A PL391988A1 PL 391988 A1 PL391988 A1 PL 391988A1 PL 39198802 A PL39198802 A PL 39198802A PL 39198802 A PL39198802 A PL 39198802A PL 391988 A1 PL391988 A1 PL 391988A1
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- pro
- derivatives
- interleukin
- thr
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000028709 inflammatory response Effects 0.000 title 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract 2
- 206010070834 Sensitisation Diseases 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 150000002668 lysine derivatives Chemical class 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000008313 sensitization Effects 0.000 abstract 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 abstract 2
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010014025 Ear swelling Diseases 0.000 abstract 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 abstract 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 abstract 1
- 102000003814 Interleukin-10 Human genes 0.000 abstract 1
- 108090000174 Interleukin-10 Proteins 0.000 abstract 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 abstract 1
- LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 230000003510 anti-fibrotic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 108010013842 interleukin 1beta (193-195) Proteins 0.000 abstract 1
- 229940076144 interleukin-10 Drugs 0.000 abstract 1
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/85—Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C12N2501/86—Melanocyte-stimulating hormone [MSH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10106852A DE10106852A1 (de) | 2001-02-14 | 2001-02-14 | Entzündungshemmende Verbindungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL391988A1 true PL391988A1 (pl) | 2010-09-13 |
| PL223478B1 PL223478B1 (pl) | 2016-10-31 |
Family
ID=7674019
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL369526A PL221492B1 (pl) | 2001-02-14 | 2002-02-08 | Zastosowanie dipeptydu lub tripeptydu do wytwarzania leków hamujących zapalenie |
| PL391884A PL223229B1 (pl) | 2001-02-14 | 2002-02-08 | Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania stanom zapalnym naczyń |
| PL391988A PL223478B1 (pl) | 2001-02-14 | 2002-02-08 | Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania odpowiedzi immunologicznej na tle zapalnym |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL369526A PL221492B1 (pl) | 2001-02-14 | 2002-02-08 | Zastosowanie dipeptydu lub tripeptydu do wytwarzania leków hamujących zapalenie |
| PL391884A PL223229B1 (pl) | 2001-02-14 | 2002-02-08 | Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania stanom zapalnym naczyń |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8003608B2 (pl) |
| EP (6) | EP2189156A1 (pl) |
| JP (1) | JP4259870B2 (pl) |
| CN (3) | CN1269477C (pl) |
| AT (2) | ATE502632T1 (pl) |
| AU (2) | AU2002253000B2 (pl) |
| CA (1) | CA2437788C (pl) |
| CY (4) | CY1106563T1 (pl) |
| DE (3) | DE10106852A1 (pl) |
| DK (4) | DK2196202T3 (pl) |
| ES (4) | ES2281511T3 (pl) |
| HK (4) | HK1140960A1 (pl) |
| MX (1) | MXPA03007255A (pl) |
| NZ (2) | NZ542406A (pl) |
| PL (3) | PL221492B1 (pl) |
| PT (4) | PT1427405E (pl) |
| SI (4) | SI1749524T1 (pl) |
| WO (1) | WO2002064131A2 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10106852A1 (de) | 2001-02-14 | 2002-09-05 | T Luger | Entzündungshemmende Verbindungen |
| ATE304021T1 (de) * | 2001-05-25 | 2005-09-15 | Vlaams Interuniv Inst Biotech | Lektin-ähnliche domäne von thrombomodulin und therapeutische verwendung davon |
| US20090232866A1 (en) | 2003-10-07 | 2009-09-17 | Mariann Pavone-Gyongyosi | Oligopeptides as coating material for medical products |
| WO2006009325A1 (ja) * | 2004-07-23 | 2006-01-26 | Ono Pharmaceutical Co., Ltd. | メタロプロテアーゼ阻害剤 |
| WO2006046746A1 (ja) * | 2004-10-26 | 2006-05-04 | Ajinomoto Co., Inc. | 内臓痛予防・治療剤 |
| WO2007004613A1 (ja) * | 2005-07-01 | 2007-01-11 | Ajinomoto Co., Inc. | 炎症性腸疾患治療薬及びＴＮＦ－α産生抑制剤 |
| EP1782819A1 (en) * | 2005-11-03 | 2007-05-09 | Cognis IP Management GmbH | Oligopeptides and their use |
| DE102006003854A1 (de) * | 2006-01-26 | 2007-08-02 | Universität Duisburg-Essen | Regulatorische und cytotoxische CD8+ T-Zellen |
| WO2009065857A2 (en) * | 2007-11-19 | 2009-05-28 | Universitätsklinikum Münster | Compositions for reducing oxidative stress and uses thereof |
| US9156881B2 (en) * | 2011-09-23 | 2015-10-13 | Westfaelische Wilhelms-Universitaet Muenster | Tripeptide KDPT for antiapoptotic treatment |
| SG11201405244RA (en) | 2012-03-20 | 2014-10-30 | Helix Biomedix Inc | Short antimicrobial lipopeptides |
| AU2014262517B2 (en) * | 2013-05-10 | 2018-10-18 | Southern Research Institute | Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-beta activity |
| EP3049428B1 (en) | 2013-09-23 | 2018-11-07 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Anti-inflammatory tripeptides |
| SG11201603440SA (en) * | 2013-11-07 | 2016-05-30 | Wolff August Gmbh & Co Kg Arzneimittel Dr | Storage stable lyophilized tripeptide formulations |
| CN107349416A (zh) * | 2017-08-01 | 2017-11-17 | 中山大学 | 一种含三肽化合物的抗骨关节炎药物 |
| CN117777239A (zh) * | 2017-09-15 | 2024-03-29 | 凯恩塞恩斯株式会社 | 作为自身免疫疾病及骨病治疗剂的肽的用途 |
| CN111150831B (zh) * | 2020-02-27 | 2023-06-09 | 广州领晟医疗科技有限公司 | 多肽KdPT的应用 |
| US11793746B2 (en) * | 2020-10-01 | 2023-10-24 | Chanda Zaveri | Intense skin hydration systems and methods |
| CN114432421B (zh) * | 2022-01-12 | 2024-04-12 | 广州领晟医疗科技有限公司 | 一种用于治疗急性肺损伤的KdPT多肽及其应用 |
| CN114404562A (zh) * | 2022-01-17 | 2022-04-29 | 广州领晟医疗科技有限公司 | 一种用于治疗骨关节炎的KdPT多肽及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH676425A5 (pl) | 1986-08-08 | 1991-01-31 | Univ Texas | |
| US4966848A (en) * | 1988-02-08 | 1990-10-30 | The General Hospital Corporation | Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase |
| ATE125548T1 (de) * | 1988-03-28 | 1995-08-15 | British Tech Group | Peptide. |
| ES2012532A6 (es) * | 1988-07-15 | 1990-04-01 | Cusi Lab | Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica. |
| DE3844046A1 (de) * | 1988-12-28 | 1990-07-05 | Hoerrmann Wilhelm | Arzneimittel, die isomere des hydroxylysins oder lysins enthalten |
| US5223421A (en) * | 1989-10-25 | 1993-06-29 | The General Hospital Corporation | Identification of methionine Nα-acetyltransferase |
| CA2073981C (en) * | 1990-11-30 | 2002-01-08 | Shiro Kondo | 2-arylthiazole derivatives and pharmaceutical composition thereof |
| ATE171373T1 (de) * | 1993-01-22 | 1998-10-15 | Pfizer | Lysin salz von 6-fluoro-3,2-(2-thenoyl)-2-oxidol- 1-carboxamid |
| GB9413935D0 (en) * | 1994-07-11 | 1994-08-31 | Peptech Uk Ltd | Use of maramyl peptide compounds |
| GB9419011D0 (en) * | 1994-09-21 | 1994-11-09 | Peptech Uk Ltd | Use of muramyl peptide compounds |
| SE9500270L (sv) * | 1995-01-25 | 1996-09-09 | A K J Medi Konsult Ab | Läkemedel mot bristtillstånd |
| WO1996023490A1 (en) | 1995-02-03 | 1996-08-08 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| FR2733421B1 (fr) | 1995-04-28 | 1997-06-06 | Oreal | Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute |
| US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| US5939394A (en) * | 1996-01-18 | 1999-08-17 | Fleming & Company | Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections |
| JP3567350B2 (ja) * | 1996-03-13 | 2004-09-22 | 株式会社ホーネンコーポレーション | 抗脱毛症剤 |
| JP3922594B2 (ja) * | 1996-03-19 | 2007-05-30 | 株式会社ノエビア | 抗菌性低刺激化粧料 |
| AU3224997A (en) * | 1996-05-29 | 1998-01-05 | Prototek, Inc | Prodrugs of thalidomide and methods for using same as modulators of t-cell function |
| US6117896A (en) * | 1997-02-10 | 2000-09-12 | Molecumetics Ltd. | Methods for regulating transcription factors |
| ATE404527T1 (de) * | 1996-10-11 | 2008-08-15 | Kowa Co | Neue diamidverbindungen und medikamente die diese enthalten |
| AUPO713297A0 (en) * | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
| SE9801571D0 (sv) * | 1998-05-05 | 1998-05-05 | Wapharm Ab | Melanokortin-1-receptorselektiva föreningar |
| FR2784028B1 (fr) * | 1998-10-01 | 2003-02-07 | Oreal | Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques |
| JP3962166B2 (ja) * | 1998-10-19 | 2007-08-22 | 株式会社資生堂 | 皮膚外用剤 |
| WO2000037071A1 (en) * | 1998-12-21 | 2000-06-29 | Aps Kbus 8 Nr. 4788 | Topical treatment of skin disease |
| JP2002534968A (ja) * | 1999-01-22 | 2002-10-22 | ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド | α−メラニン細胞刺激ホルモンによる調節Ｔ細胞の活性化 |
| WO2000054750A1 (fr) * | 1999-03-15 | 2000-09-21 | Dmitry Anatolievich Starchenko | Procede de correction des perturbations dans la synthese du collagene et substance bioactive de mise en oeuvre de ce procede |
| US7169603B2 (en) * | 2000-07-14 | 2007-01-30 | Mgi Pharma Biologics, Inc. | α-MSH related compounds and methods of use |
| DE10106852A1 (de) | 2001-02-14 | 2002-09-05 | T Luger | Entzündungshemmende Verbindungen |
| US7960508B2 (en) | 2001-05-11 | 2011-06-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Peptide having cytotoxicity inhibitory activity and method of screening these peptide having cytotoxicity inhibitory activity |
-
2001
- 2001-02-14 DE DE10106852A patent/DE10106852A1/de not_active Ceased
-
2002
- 2002-02-08 EP EP10154667A patent/EP2189156A1/de not_active Withdrawn
- 2002-02-08 SI SI200230937T patent/SI1749524T1/sl unknown
- 2002-02-08 DE DE50209873T patent/DE50209873D1/de not_active Expired - Lifetime
- 2002-02-08 DK DK10154655.4T patent/DK2196202T3/da active
- 2002-02-08 JP JP2002563925A patent/JP4259870B2/ja not_active Expired - Fee Related
- 2002-02-08 PL PL369526A patent/PL221492B1/pl not_active IP Right Cessation
- 2002-02-08 SI SI200231025T patent/SI2198723T1/sl unknown
- 2002-02-08 CN CNB028072634A patent/CN1269477C/zh not_active Expired - Lifetime
- 2002-02-08 ES ES02722056T patent/ES2281511T3/es not_active Expired - Lifetime
- 2002-02-08 PT PT02722056T patent/PT1427405E/pt unknown
- 2002-02-08 PT PT06024288T patent/PT1749524E/pt unknown
- 2002-02-08 CN CN2010101261369A patent/CN101810847B/zh not_active Expired - Lifetime
- 2002-02-08 WO PCT/EP2002/001323 patent/WO2002064131A2/de active IP Right Grant
- 2002-02-08 DK DK06024288.0T patent/DK1749524T3/da active
- 2002-02-08 AU AU2002253000A patent/AU2002253000B2/en not_active Ceased
- 2002-02-08 EP EP10181894A patent/EP2260843A3/de not_active Withdrawn
- 2002-02-08 AT AT06024288T patent/ATE502632T1/de active
- 2002-02-08 ES ES10154655T patent/ES2427970T3/es not_active Expired - Lifetime
- 2002-02-08 PT PT101546554T patent/PT2196202E/pt unknown
- 2002-02-08 EP EP06024288A patent/EP1749524B1/de not_active Expired - Lifetime
- 2002-02-08 CA CA2437788A patent/CA2437788C/en not_active Expired - Lifetime
- 2002-02-08 US US10/467,993 patent/US8003608B2/en not_active Expired - Fee Related
- 2002-02-08 PL PL391884A patent/PL223229B1/pl unknown
- 2002-02-08 DK DK10154643.0T patent/DK2198723T3/da active
- 2002-02-08 DE DE50214981T patent/DE50214981D1/de not_active Expired - Lifetime
- 2002-02-08 PT PT101546430T patent/PT2198723E/pt unknown
- 2002-02-08 DK DK02722056T patent/DK1427405T3/da active
- 2002-02-08 EP EP02722056A patent/EP1427405B1/de not_active Expired - Lifetime
- 2002-02-08 SI SI200231032T patent/SI2196202T1/sl unknown
- 2002-02-08 ES ES10154643T patent/ES2411935T3/es not_active Expired - Lifetime
- 2002-02-08 AT AT02722056T patent/ATE358475T1/de active
- 2002-02-08 EP EP10154655.4A patent/EP2196202B1/de not_active Expired - Lifetime
- 2002-02-08 SI SI200230541T patent/SI1427405T1/sl unknown
- 2002-02-08 MX MXPA03007255A patent/MXPA03007255A/es active IP Right Grant
- 2002-02-08 PL PL391988A patent/PL223478B1/pl unknown
- 2002-02-08 NZ NZ542406A patent/NZ542406A/en not_active IP Right Cessation
- 2002-02-08 EP EP10154643.0A patent/EP2198723B1/de not_active Expired - Lifetime
- 2002-02-08 CN CN2006100925582A patent/CN101215544B/zh not_active Expired - Fee Related
- 2002-02-08 ES ES06024288T patent/ES2361422T3/es not_active Expired - Lifetime
- 2002-02-08 NZ NZ528191A patent/NZ528191A/en not_active IP Right Cessation
-
2004
- 2004-07-13 HK HK10107497.1A patent/HK1140960A1/xx not_active IP Right Cessation
- 2004-07-13 HK HK04105100A patent/HK1061980A1/xx not_active IP Right Cessation
- 2004-07-13 HK HK07102834.9A patent/HK1095538A1/xx not_active IP Right Cessation
- 2004-07-13 HK HK10107436.5A patent/HK1140915A1/xx not_active IP Right Cessation
-
2006
- 2006-08-22 AU AU2006203622A patent/AU2006203622B2/en not_active Ceased
-
2007
- 2007-05-07 CY CY20071100596T patent/CY1106563T1/el unknown
-
2011
- 2011-05-04 CY CY20111100430T patent/CY1111450T1/el unknown
- 2011-07-16 US US13/184,518 patent/US8846617B2/en not_active Expired - Fee Related
-
2013
- 2013-05-30 CY CY20131100431T patent/CY1114024T1/el unknown
- 2013-08-14 CY CY20131100702T patent/CY1114214T1/el unknown
-
2014
- 2014-08-25 US US14/467,217 patent/US9550807B2/en not_active Expired - Lifetime
-
2016
- 2016-12-14 US US15/379,047 patent/US10046020B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL391988A1 (pl) | Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania odpowiedzi immunologicznej na tle zapalnym | |
| Ceriani et al. | The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats | |
| US20030190303A1 (en) | Lactoferrin as regulator of allergen-induced tumor necrosis factor-alpha production and therapeutic applications | |
| JP2000510844A (ja) | モノホスホリルリピドａを用いてｉ型過敏症を治療する方法 | |
| Yehuda et al. | Thermoregulatory and locomotor effects of DSIP: paradoxical interaction with d-amphetamine | |
| US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
| CA2501738A1 (en) | Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| Strannegård et al. | Adjuvant effect of lysolecithin analogues on the development of contact sensitivity in mice | |
| AU2009317356A1 (en) | Use of escin for treatment of Type IV hypersensitivity reaction | |
| JP2011190274A (ja) | 炎症反応により生ずる哺乳動物の鼻および副鼻洞の病気を処置する方法および組成物 | |
| US4689213A (en) | Method and composition for treating bronchospastic airway diseases | |
| Malo et al. | Inhibition by auranofin of pharmacologic and antigen-induced contractions of the isolated guinea pig trachea | |
| WO1999000079A1 (en) | Skin aging and wound treatment using cell migration agents | |
| Nakamoto et al. | Effect of allergen immunotherapy on nasal responses in guinea‐pigs with allergic rhinitis | |
| WO2002001956A1 (en) | Histidyl-proline diketopiperazine and method of use | |
| Lepistö et al. | Stimulation of wound healing by the immunomodulator LS-2616 (Linomide) | |
| RU99108220A (ru) | Способ лечения острого периода гипоталамического синдрома пубертатного периода | |
| Tanaka et al. | Evaluation of an antiallergic agent (disodium cromoglycate) in rat conjunctiva using monoclonal IgE antibody | |
| RU2185161C2 (ru) | Способ повышения иммунологической резистентности | |
| ITBO950465A1 (it) | Modo di assunzione di vitamina c e mono-disaccaridi in pozione per uso umano, normalizzatrice dei ph intestinale e sanguigno alterati da | |
| Barcellini et al. | Effect of isoxicam treatment on in vivo and in vitro immunological parameters. | |
| Kurwa et al. | Treatment of pretibial myxoedema with PUVA | |
| WO2005018580A3 (en) | Anti-cancer virus desensitization method | |
| RU94033867A (ru) | Способ стимуляции apud-системы |